GLP1R and chronic kidney disease: The KDIGO guidelines recommend the use of GLP-1 receptor agonists in patients with type 2 diabetes and CKD who have not achieved individualized glycemic goals despite the use of metformin and SGLT2i, or who are unable to use these drugs [90].